- Amarin's gross margin has been growing from year to year and by the end of Q2 2021 was around 79.2%, which is significantly higher than the average for the healthcare.
- Vascepa sales increased 15% in Q2 2021 compared to Q2 2020.
- In the next 18 months, the company should begin commercializing Vazkepa in several countries of the European Union, which will contribute to a multi-million increase in potential patients.
- Vascepa will likely be approved in China by the end of 2021, based on several clinical studies confirming the efficacy and safety of this medicine.
- Vascepa is the only drug approved by the FDA and EMA for the reduction of certain types of heart disease in high-risk patients as an adjunct to statin therapy.
For further details see:
Amarin: Maximum Optimism